PepTalk 2017
PepTalk 2017

CONFERENCE SERIES: Bioprocess & Manufacturing

Recorded at: PepTalk: The Protein Science Week

Digital Course: Characterization and Analysis of Visible and Sub-Visible Particulates

Order DVD2012 Characterization and Analysis of Particulates DVD Cover About this Product: 

Sub-visible particles present in these biopharmaceutical products are a product quality attribute and a potential patient safety concerns yet to be fully explored. Early and consistent particle detection, quantitation and control throughout the product life cycle of these drugs from development to commercial lot release is critical in mitigating any concerns. This requires appropriate analytical methods which can be applied to biopharmaceuticals across a large variety of protein concentrations and modes of administration. This digital course will cover strategies to utilize complementary methods and techniques at different phases of product development. You will learn:

  • Different protein aggregation mechanisms
  • Influence of sample handling and solvent history on aggregation
  • Orthogonal methods
  • Non-invasive methods to detect small amounts of aggregates




About this Product:
2 Presentations
276 Slides
Over 147 Minutes
Individual: $345
Site License: $1380

Agenda At A Glance: 

Part 1: Mechanisms of Protein Aggregation
Part 2: Analytical Methods

Speaker and Biography: 

Tudor ArvinteInstructor: Tudor Arvinte, Ph.D., Professor, Department of Biopharmaceutics, University of Geneva; CEO, Therapeomic Inc.Tudor Arvinte was born in Romania, received his Ph.D. in biophysics from the University of Düsseldorf, Germany. He held research positions in Europe (Max-Planck-Institute, C.N.R.S.) and in U.S.A. (Cornell University and Texas A&M University). He joined Ciba-Geigy in England, and then Ciba-Geigy/ Novartis Basel where he was Head of Exploratory Formulation for biotech products. Tudor worked on the formulation of more than 60 proteins, has over 60 publications and 11 patents. He is Associated Professor at the School of Pharmacy, University of Geneva.  In 2003, he co-founded Therapeomic, Inc., a biotech company focused on developing formulations for biopharmaceuticals in collaborations with pharmaceutical companies.

About the Conference: 

PepTalk 2012 continues the tradition of strong scientific programming centered around protein-based therapeutics.  The four distinct protein pipelines focused on formulation, purification, biotherapeutics and expression range from applying protein discovery research, to developing downstream protein products that ultimately lead to clinical applications.  This focused design enables you create your own agenda by moving between the tracks and choosing the sessions that best fit your research and networking needs.  Additional networking opportunities will be available through BuzZ Session discussion groups, short courses and panel discussions.